Abbott Q4 Diagnostics Revenues up 111 Percent, FY20 Revenues up 9 Percent

Jan 27, 2021

|

Note: This story has been updated with comments from Abbott's earnings call.

NEW YORK — Abbott reported Wednesday that its fourth quarter diagnostics revenues rose 111 percent year over year due to strong sales related to the firm's COVID-19 products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Abbott Q4 Diagnostics Revenues up 111 Percent, FY20 Revenues up 9 Percent

To read the full story....

Breaking News

FDA Grants Emergency Use Authorization for University of Illinois Coronavirus PCR Test

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Sponsorships